Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results from a Large Multicenter Trial.

Thompson JF, Haydu LE, Uren RF, Andtbacka RH, Zager JS, Beitsch PD, Agnese DM, Mozzillo N, Testori A, Bowles TL, Hoekstra HJ, Kelley MC, Sussman J, Schneebaum S, Smithers BM, McKinnon G, Hsueh E, Jacobs L, Schultz E, Reintgen D, Kane JM, Friedman EB, Wang H, Van Kreuningen L, Schiller V, Elashoff DA, Elashoff R, Cochran AJ, Stern S, Faries MB; MSLT-II Trial Group.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003405. [Epub ahead of print]

PMID:
31188198
2.

Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2019 Jan;7(1):86-99. doi: 10.1158/2326-6066.CIR-17-0692. Epub 2018 Nov 9.

PMID:
30413431
3.

HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Preexposure Prophylaxis During Pregnancy.

Pintye J, Beima-Sofie KM, Makabong'O PA, Njoroge A, Trinidad SB, Heffron RA, Baeten JM, Celum C, Matemo D, Kinuthia J, Kelley MC, John-Stewart GC.

AIDS Patient Care STDS. 2018 Jul 23. doi: 10.1089/apc.2018.0058. [Epub ahead of print]

PMID:
30036072
4.

The Massive Auditory Lexical Decision (MALD) database.

Tucker BV, Brenner D, Danielson DK, Kelley MC, Nenadić F, Sims M.

Behav Res Methods. 2019 Jun;51(3):1187-1204. doi: 10.3758/s13428-018-1056-1.

PMID:
29916041
5.

BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.

Doxie DB, Greenplate AR, Gandelman JS, Diggins KE, Roe CE, Dahlman KB, Sosman JA, Kelley MC, Irish JM.

Pigment Cell Melanoma Res. 2018 Nov;31(6):708-719. doi: 10.1111/pcmr.12712. Epub 2018 Jun 28.

PMID:
29778085
6.

The role of male partners in women's participation in research during pregnancy: a case study from the partners demonstration project.

Ngure K, Trinidad SB, Beima-Sofie K, Baeten JM, Mugo NR, Bukusi EA, Heffron R, John-Stewart G, Kelley MC.

Reprod Health. 2017 Dec 14;14(Suppl 3):160. doi: 10.1186/s12978-017-0424-0.

7.

Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment.

Thomas G, Nguyen TQ, Pence IJ, Caldwell B, O'Connor ME, Giltnane J, Sanders ME, Grau A, Meszoely I, Hooks M, Kelley MC, Mahadevan-Jansen A.

Sci Rep. 2017 Oct 19;7(1):13548. doi: 10.1038/s41598-017-13237-y.

8.

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A.

EBioMedicine. 2017 Oct;24:43-55. doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19.

9.

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group.

Ann Surg Oncol. 2017 Dec;24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10.

PMID:
29019177
10.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

11.

Understanding Animal Detection of Precursor Earthquake Sounds.

Garstang M, Kelley MC.

Animals (Basel). 2017 Aug 31;7(9). pii: E66. doi: 10.3390/ani7090066.

12.

"I Did Not Want to Give Birth to a Child Who has HIV": Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples.

Pintye J, Beima-Sofie KM, Kimemia G, Ngure K, Trinidad SB, Heffron RA, Baeten JM, Odoyo J, Mugo N, Bukusi EA, Kelley MC, John-Stewart GC.

J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):259-265. doi: 10.1097/QAI.0000000000001516.

13.

Single Cell Analysis of Human Tissues and Solid Tumors with Mass Cytometry.

Leelatian N, Doxie DB, Greenplate AR, Mobley BC, Lehman JM, Sinnaeve J, Kauffman RM, Werkhaven JA, Mistry AM, Weaver KD, Thompson RC, Massion PP, Hooks MA, Kelley MC, Chambless LB, Ihrie RA, Irish JM.

Cytometry B Clin Cytom. 2017 Jul 18. doi: 10.1002/cyto.b.21542. [Epub ahead of print] No abstract available.

14.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

15.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2017 Jan 26;168(3):542. doi: 10.1016/j.cell.2017.01.010. No abstract available.

16.

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A.

Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. doi: 10.1158/1078-0432.CCR-16-2142. Epub 2016 Dec 21. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3782.

17.

Single cell analysis of human tissues and solid tumors with mass cytometry.

Leelatian N, Doxie DB, Greenplate AR, Mobley BC, Lehman JM, Sinnaeve J, Kauffmann RM, Werkhaven JA, Mistry AM, Weaver KD, Thompson RC, Massion PP, Hooks MA, Kelley MC, Chambless LB, Ihrie RA, Irish JM.

Cytometry B Clin Cytom. 2017 Jan;92(1):68-78. doi: 10.1002/cyto.b.21481. Epub 2016 Oct 4.

18.

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?

Kelley MC.

Crit Rev Oncog. 2016;21(1-2):83-91. doi: 10.1615/CritRevOncog.2016017150. Review.

PMID:
27481005
19.

Ethical challenges in research with orphans and vulnerable children: a qualitative study of researcher experiences.

Kelley MC, Brazg T, Wilfond BS, Lengua LJ, Rivin BE, Martin-Herz SP, Diekema DS.

Int Health. 2016 May;8(3):187-96. doi: 10.1093/inthealth/ihw020.

PMID:
27178675
20.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17. Erratum in: Cell. 2017 Jan 26;168(3):542.

21.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM.

Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582.

22.

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB.

Pigment Cell Melanoma Res. 2016 Jan;29(1):101-3. doi: 10.1111/pcmr.12394. Epub 2015 Aug 20. No abstract available.

PMID:
26176864
23.

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

Clin Cancer Res. 2015 Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7.

24.

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Johnson DB, Puzanov I, Kelley MC.

Immunotherapy. 2015;7(6):611-9. doi: 10.2217/imt.15.35. Epub 2015 Jun 22. Review.

25.

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.

Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W.

Oncotarget. 2015 Sep 8;6(26):22348-60.

26.

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.

Johnson AS, Crandall H, Dahlman K, Kelley MC.

J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.

PMID:
25797743
27.

Predation risk, resource quality, and reef structural complexity shape territoriality in a coral reef herbivore.

Catano LB, Gunn BK, Kelley MC, Burkepile DE.

PLoS One. 2015 Feb 25;10(2):e0118764. doi: 10.1371/journal.pone.0118764. eCollection 2015.

28.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

29.

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.

30.

Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE.

Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100.

31.

Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.

Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Fair AM, Sanderson M, Shu XO, Kelley MC, Zheng W.

Clin Breast Cancer. 2014 Dec;14(6):417-25. doi: 10.1016/j.clbc.2014.04.003. Epub 2014 Jun 2.

32.

Melanoma, version 4.2014.

Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):621-9.

PMID:
24812131
33.

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA.

Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.

34.

Care taker blogs in caregiver fabricated illness in a child: a window on the caretaker's thinking?

Brown AN, Gonzalez GR, Wiester RT, Kelley MC, Feldman KW.

Child Abuse Negl. 2014 Mar;38(3):488-97. doi: 10.1016/j.chiabu.2013.12.002. Epub 2014 Jan 4.

35.

Triage in the Tower of Babel: interpreter services for children in the prehospital setting.

Tate RC, Kelley MC.

Pediatr Emerg Care. 2013 Dec;29(12):1280-2. doi: 10.1097/PEC.0000000000000034.

PMID:
24300472
36.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

37.

APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.

Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, Kelley MC, Zheng W, Long J.

Carcinogenesis. 2013 Oct;34(10):2240-3. doi: 10.1093/carcin/bgt185. Epub 2013 May 28.

38.

DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE.

Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9.

39.

Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma.

Sexton KW, Poteet SP, Hill JB, Schmidt A, Patel A, Del Corral GA, Axt J, Kelley MC, Thayer WP, Shack RB.

Ann Plast Surg. 2014 Nov;73(5):531-4. doi: 10.1097/SAP.0b013e31827f4c58.

PMID:
23657045
40.

Melanoma, version 2.2013: featured updates to the NCCN guidelines.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):395-407.

PMID:
23584343
41.

On the Possible Detection of Lightning Storms by Elephants.

Kelley MC, Garstang M.

Animals (Basel). 2013 Apr 18;3(2):349-55. doi: 10.3390/ani3020349.

42.

Silent loss and the clinical encounter: Parents' and physicians' experiences of stillbirth-a qualitative analysis.

Kelley MC, Trinidad SB.

BMC Pregnancy Childbirth. 2012 Nov 27;12:137. doi: 10.1186/1471-2393-12-137.

43.

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

EMBO Mol Med. 2013 Jan;5(1):149-66. doi: 10.1002/emmm.201201378. Epub 2012 Nov 25.

44.

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W.

PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20.

45.

Melanoma.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Mar;10(3):366-400. No abstract available.

PMID:
22393197
46.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

47.

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS.

Ann Surg. 2012 Feb;255(2):357-62. doi: 10.1097/SLA.0b013e3182380f56.

48.

Biodefence and the production of knowledge: rethinking the problem.

Buchanan A, Kelley MC.

J Med Ethics. 2013 Apr;39(4):195-204. doi: 10.1136/medethics-2011-100387. Epub 2011 Dec 22.

PMID:
22194319
49.

Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer.

Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE.

Magn Reson Med. 2012 Jul;68(1):261-71. doi: 10.1002/mrm.23205. Epub 2011 Nov 29.

50.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.

Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

Supplemental Content

Loading ...
Support Center